INSIGHTS INTO ADDRESSING EARLY SCHIZOPHRENIA: PRODROME AND FIRST EPISODE
|
|
- Melinda Caldwell
- 5 years ago
- Views:
Transcription
1
2 INSIGHTS INTO ADDRESSING EARLY SCHIZOPHRENIA: PRODROME AND FIRST EPISODE S. Charles Schulz, MD Professor & Head Donald W. Hastings Endowed Chair Department of Psychiatry University of Minnesota Medical School Minneapolis, MN
3 INSIGHTS INTO ADDRESSING EARLY SCHIZOPHRENIA: PRODROME AND FIRST EPISODE Jeffrey A. Lieberman, MD Chairman, Department of Psychiatry College of Physicians and Surgeons, Columbia University Director, New York State Psychiatric Institute Director, Lieber Center for Schizophrenia Research Psychiatrist-in-Chief at New York Presbyterian Hospital and Columbia University Medical Center New York, NY
4 S. CHARLES SCHULZ, MD Disclosures Research/Grants: AstraZeneca Pharmaceuticals LP; Otsuka America Pharmaceutical, Inc.; Rules-Based Medicine, Inc. Speakers Bureau: None Consultant: Biovail Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Lilly USA, LLC Stockholder: None Other Financial Interest: None Advisory Board: None
5 JEFFREY A. LIEBERMAN, MD Disclosures* Research/Grants: Allon Therapeutics; F. Hoffmann-La Roche LTD; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sepracor Inc.; Targacept, Inc. Speakers Bureau: None Consultant: Bioline; GlaxoSmithKline; Intra-Cellular Therapies, Inc.; Lilly USA, LLC; Pierre Fabre Laboratories; PsychoGenics, Inc. Stockholder: None Other Financial Interest: Patent from Repligen Corporation Advisory Board: None * Receives no personal financial remuneration for these activities
6 LEARNING OBJECTIVE Improve recognition and management of early-onset schizophrenia.
7 SCHIZOPHRENIA PRODROME: COMPELLING DATA, EMERGING INSIGHTS
8 EARLY REFLECTIONS ABOUT THE PRODROME From Dr. H.S. Sullivan as retrieved by Dr. Patrick McGorry I feel certain that many incipient cases might be arrested before the efficient contact with reality is completely suspended, and a long stay in institutions made necessary. the long[er] psychotic collapse is escaped, the less the chance of a grave disorder, and the less typical any illness which ensues. In other words a psychosis occurring in a psychopathic youth under, say, the age of 22, is in all likelihood frankly schizophrenic; but an initial psychosis occurring at, say, 30 will probably be a brief excitement. Zipursky RB and Schulz SC. In: The early stages of schizophrenia
9 EARLY-ONSET SCHIZOPHRENIA COURSE Normal Early-Onset Schizophrenia Course Premorbid Prodromal Deterioration Chronic/Residual Severity of Symptoms and Disability Gestation/ Birth Puberty Adolescence Adult Middle Age Developmental Stage Senescence Lieberman JA, et al. Biol Psychiatry. 2001;50(11):
10 PRODROMAL HOT TOPICS Can the prodrome be accurately identified using symptoms, biomarkers, family history (or genes)? Are there ways to specify the direction of prodromal symptoms in order to apply specific treatments? Are there adequate data to recommend treatment approaches to the prodrome? In other branches of medicine, there are concerns of overdiagnosis of early stages of illness; how can such concerns be dealt with in the prodrome?
11 ON PREDICTING FUTURE PSYCHOSIS Prediction of Psychosis in Youth at High Clinical Risk: A Multisite Longitudinal Study in North America. Cannon TD, et al. Arch Gen Psychiatry. 2008;65(1): Cannon TD, et al. Arch Gen Psychiatry. 2008;65(1):28-37.
12 CANNON ET AL, 2008 Overview and Methods Clinical question under investigation Can algorithms be constructed to maximize predictive power of conversion to psychosis in a high-risk sample? Methods N = 291 Treatment-seeking patients at 8 sites in the North American Prodrome Longitudinal Study (NAPLS) Followed for 2.5 years Cannon TD, et al. Arch Gen Psychiatry. 2008;65(1):28-37.
13 CANNON ET AL, 2008 Results Conversion rate was 35% 5 variables uniquely predictive of psychosis 1. Significant prediction of genetic risk of schizophrenia 2. Higher levels of unusual thought content 3. Higher levels of paranoia 4. Greater social impairment 5. History of substance abuse Algorithms combining 2 or 3 of these variables resulted in dramatic increases in positive predictive power (PPP) of 68% to 80% 81% PPP for 1, 2, and 4 and 1, 2, 3, 4 Cannon TD, et al. Arch Gen Psychiatry. 2008;65(1):28-37.
14 CANNON ET AL, 2008 Conclusions Authors conclusions Prospective prediction of patients as high risk for psychosis is feasible The level of predictive accuracy is at a level of other areas of preventive medicine Cannon TD, et al. Arch Gen Psychiatry. 2008;65(1):28-37.
15 ON ABNORMAL NEUROANATOMY AND SYMPTOM ONSET Neuroanatomical Abnormalities Before and After Onset of Psychosis: A Cross-Sectional and Longitudinal MRI Comparison Pantelis C, et al. Lancet. 2003;361(9354): Pantelis C, et al. Lancet. 2003;361(9354):
16 PANTELIS ET AL, 2003 Overview and Methods Clinical question under investigation Do the neuroanatomical abnormalities in the brain predate symptoms in patients with schizophrenia? Methods Subjects with prodrome, N = 75 MRI scan at baseline and at 1 year Pantelis C, et al. Lancet. 2003;361(9354):
17 PANTELIS ET AL, 2003 Results and Conclusions 31% (n = 23) developed psychosis At baseline: Significant reductions in grey matter were seen between the subjects who became psychotic and those who did not After 12 months: More areas of grey matter reduction were noted Authors conclusions Some of the grey matter abnormalities associated with psychotic disorders predate the onset of frank symptoms, whereas others appear later Pantelis C, et al. Lancet. 2003;361(9354):
18 ON INTERVENING DURING THE PRODROME Randomized Controlled Trial of Interventions Designed to Reduce the Risk of Progression to First-episode Psychosis in a Clinical Sample with Subthreshold Symptoms McGorry PD, et al. Arch Gen Psychiatry. 2002;59(10): No pharmacotherapy agent is FDA approved for reduction in risk of progression to frank psychosis. McGorry PD, et al. Arch Gen Psychiatry. 2002;59(10):
19 MCGORRY ET AL, 2002 Overview and Methods Clinical question under investigation Can pharmacotherapy interventions during the prodrome alter risk of progression to psychosis? Methods Initial phase of the trial was 6 months N = 59 subjects at ultra high risk for progression to first-episode psychosis Treatment arms RIS + CBT (mean dose 1.3 mg/day) Needs-based intervention McGorry PD, et al. Arch Gen Psychiatry. 2002;59(10):
20 MCGORRY ET AL, 2002 Results and Conclusions At 6 months, progression to first-episode 3/31 RIS + CBT p =.03 10/28 Needs-based intervention After another 6 months: Groups were no longer different Protection against progression extended for 6 months after cessation of RIS use Authors conclusions There was a reduction in early transition to psychosis with more specific treatment McGorry PD, et al. Arch Gen Psychiatry. 2002;59(10):
21 ON INTERVENING DURING THE PRODROME Randomized Controlled Trial of Interventions For Young People at Ultra High Risk for Psychosis: 6-Month Analysis Yung AR, et al. J Clin Psychiatry. 2011;72(4): No pharmacotherapy agent is FDA approved for reduction in risk of progression to frank psychosis. Yung AR, et al. J Clin Psychiatry. 2011;72(4):
22 YUNG ET AL, 2011 Overview and Methods Clinical question under investigation Can CBT and/or pharmacotherapy employed during the schizophrenia affect outcomes? Methods 6-month RCT N = 115 randomized subjects into one of three groups CBT + RIS CBT + PBO Supportive + PBO N = 78 additional nonrandomized subjects who agreed to undergo assessment Yung AR, et al. J Clin Psychiatry. 2011;72(4):
23 YUNG ET AL, 2011 Results and Conclusions Proportions developing psychosis: 8/115 randomized subjects 4/78 nonrandomized subjects No difference between the randomized groups Authors conclusions The authors discuss the power of the study The interventions may be equally effective Yung AR, et al. J Clin Psychiatry. 2011;72(4):
24 ON INTERVENING DURING THE PRODROME Long-Chain Omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial Amminger GP, et al. Arch Gen Psychiatry. 2010;67(2): No pharmacotherapy agent is FDA approved for reduction in risk of progression to frank psychosis. Amminger GP, et al. Arch Gen Psychiatry. 2010;67(2):
25 AMMINGER ET AL, 2010 Overview and Methods Clinical question under investigation Can omega-3 fatty acids reduce rate of progression to psychosis in patients with subthreshold psychosis? Methods 12-month RCT 81 subjects at ultra-high risk of psychotic disorder Treatment arms Omega-3 fatty acids PBO Amminger GP, et al. Arch Gen Psychiatry. 2010;67(2):
26 AMMINGER ET AL, 2010 Results Amminger GP, et al. Arch Gen Psychiatry. 2010;67(2):
27 AMMINGER ET AL, 2010 Results and Conclusions 76/81 subjects completed the trial Converted to psychosis 2/41 11/40 Omega-3 fatty acids PBO Reduced symptoms with Authors conclusions Omega-3 fatty acids There was reduction of conversion to a psychotic disorder with omega-3 fatty acid therapy Omega-2 fatty acid therapy was safe Amminger GP, et al. Arch Gen Psychiatry. 2010;67(2):
28 ON OUTCOMES FOR NONCONVERTERS At Clinical High Risk for Psychosis: Outcome for Non-Converters Addington J, et al. Am J Psychiatry Apr 15 [Epub ahead of print]. Addington J, et al. Am J Psychiatry April 15 [Epub ahead of print].
29 ADDINGTON ET AL, 2011 Overview and Methods Clinical question under investigation What are outcomes for nonconverters? Methods Subjects 111 Nonconverters 139 Controls Nonconverters had at least one follow-up visit in the NAPLS group, did not become psychotic, and did not receive antipsychotic medication Controls were non-psychiatric comparison subjects Addington J, et al. Am J Psychiatry April 15 [Epub ahead of print].
30 ADDINGTON ET AL, 2011 Results and Conclusions Nonconverters Did improve in ratings and function as a group during the first year 43% had an Axis II disorder Had poorer social and role function than control subjects Authors conclusions Some patients have the onset of a psychotic illness while some remit Some subjects who didn t convert continued to have symptoms and poor function Addington J, et al. Am J Psychiatry April 15 [Epub ahead of print].
31 CLINICAL CONNECTIONS There may be a bipolar prodrome, but it may be difficult to distinguish it from SZ subjects Some of the grey matter abnormalities associated with psychotic disorders predate the onset of frank symptoms
32 CLINICAL CONNECTIONS In high-risk patients: Symptom characteristics during the prodrome can help predict risk of progression Emerging, investigational data are mixed Help-seeking prodromal patients who do not nonconvert to psychosis often have poor functioning and likely represent a group truly at high risk
33 PREVENTING DISABILITY FROM SCHIZOPHRENIA WITH EARLY INTERVENTION
34 CAN WE PREVENT THE PROGRESSION AND DISABILITY OF SCHIZOPHRENIA? Stages of Illness Premorbid Prodromal Onset/Progression Healthy Worsening Severity of Signs and Symptoms First Break Deterioration Chronic/Residual Puberty Gestation/Birth Years Lieberman JA, et al. Biol Psychiatry. 2001;50(11):
35 GRAY MATTER VOLUME CHANGES IN THE COURSE OF SCHIZOPHRENIA Courtesy of Jay Giedd and Paul Thompson.
36 CHEMICAL NEUROTRANSMISSION AND CONNECTIVITY Postmortem Brain Tissue Normal Control Dendrites Cell body Axon Person with Schizophrenia Person with Schizophrenia Glantz, Lewis
37 CAN RX ALTER THE COURSE OF SCZ? RCT of First-Episode Psychosis Outcomes Measured by Symptoms and Brain Morphology Cumulative Number of Remissions p =.11 Remission Rate Haloperidol Olanzapine p =.08 0 N = Weeks on Treatment Remission = Response for 4 consecutive weeks; Response = no ratings > 3 (mild) on PANSS items P1, P2, P3, P5, and P6 and CGI-Severity 4 Lieberman JA, et al. Arch Gen Psychiatry. 2005;62(4):
38 MR IMAGING BRAIN STRUCTURE AND TREATMENT EFFECTS IN SCHIZOPHRENIA cortex white matter 3D morphology ventricles
39 WHOLE BRAIN GRAY MATTER VOLUMES OVER 52 WEEKS ON MRI Volume (cc) Healthy volunteers (n = 58) Patients (n = 75) Haloperidol Olanzapine 600 Relative Week of Therapy Lieberman JA, et al. Arch Gen Psychiatry. 2005;62(4):
40 WHOLE BRAIN GRAY MATTER VOLUMES OVER 52 WEEKS ON MRI Volume (cc) Healthy volunteers (n = 58) Patients (n = 75) Haloperidol Olanzapine 600 Relative Week of Therapy Lieberman JA, et al. Arch Gen Psychiatry. 2005;62(4):
41 Lieberman JA, et al. Arch Gen Psychiatry. 2005;62(4):
42 CAUSAL ASSOCIATIONS AMONG MRI, SYMPTOMS, AND COGNITIVE RESPONSE TO TREATMENT Symptoms Treatment MRI brain changes Cognition Function
43 NATURAL HISTORY OF SCHIZOPHRENIA RATIONALE FOR EARLY DETECTION AND INTERVENTION Healthy Worsening Severity of Signs and Symptoms Premorbid Abnormal Brain Development Stages of Illness Chronic/ Residual End-Stage Deterioration Margin of Prevention Prodromal/Onset/ Deterioration Sensitization by dopamine Excitatory Neurotoxicity of glutamate Neurochemical Neurodegeneration? Dysregulation Gestation/Birth 10 Puberty Years Lieberman JA, et al. Biol Psychiatry. 2001;50(11):
44 LIMITATIONS OF EXISTING INTERVENTIONS FOR FEP Long Duration of Untreated Psychosis Inadequate Interventions High Attrition Rates
45 RISK OF REHOSPITALIZATION AFTER A FIRST HOSPITALIZATION FOR SCHIZOPHRENIA, BY ANTIPSYCHOTIC TREATMENT PATTERN (N = 2,588) Tiihonen J, et al. Am J Psychiatry. 2011;168(6):
46 EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS IN FIRST-EPISODE SCHIZOPHRENIA Time to Treatment Discontinuation Kahn RS, et al. Lancet. 2008;371(9618):
47 Positive and Negative Syndrome Scale (PNSS) Total Score During 12-Month Follow-Up Clinical Global Impression (CGI) Global Assessment of Functioning (GAF) Kahn RS, et al. Lancet. 2008;371(9618):
48 GRAY MATTER VOLUME CHANGES IN SCHIZOPHRENIA Courtesy of Jay Giedd and Paul Thompson
49 TREATMENT EFFECTS ON BRAIN VOLUME TRAJECTORIES White Matter Ventricles Gray Matter Ho BC, et al. Arch Gen Psychiatry. 2011;68(2):
50 SUMMARY AND CLINICAL CONNECTIONS Schizophrenia is a progressive disorder that derives from a genetically mediated neurodevelopmental diathesis The clinical deterioration and enduring nature of its morbidity is due to structural pathology in frontal and temporal regions Antipsychotic drugs target psychosis and may prevent progression Early intervention and maintenance effective Other stages and symptom dimensions require new therapeutic strategies and targets Early detection and intervention requires better diagnostic methods, interventions and models of service delivery
51 QUESTIONS AND ANSWERS
52
#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Bending the Illness Curve: A New Treatment Model for Early Stage Psychoses Jeffrey A. Lieberman, M.D. Columbia University College
More informationRECEPTOR TARGETS IN SCHIZOPHRENIA: LINKING RECEPTORS TO SYMPTOMS. Jeffrey A. Lieberman, MD Columbia University
RECEPTOR TARGETS IN SCHIZOPHRENIA: LINKING RECEPTORS TO SYMPTOMS Jeffrey A. Lieberman, MD Columbia University JEFFREY A. LIEBERMAN, MD Disclosures Research/Grants: Allon Therapeutics; Forest Laboratories,
More informationIdentifying Youth at Clinical High Risk for Psychosis
Identifying Youth at Clinical High Risk for Psychosis Jean Addington PhD University of Calgary Department of Psychiatry 1 Identifying Youth at Clinical High Risk for Psychosis Part 1: What do we know about
More informationEarly Detection & Intervention for Psychotic Disorders: Is it ready for prime time?
Early Detection & Intervention for Psychotic Disorders: Is it ready for prime time? Jeffrey Lieberman, M.D. Columbia University College of Physicians and Surgeons New York State Psychiatric Institute New
More informationThe outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry
The outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry Robin M Murray Department of Psychosis Studies Institute of Psychiatry King s College London robin.murray@kcl.ac.uk
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Schizophrenia and Cognition Jeffrey A. Lieberman, MD Columbia University College of Physicians and Surgeons New York State Psychiatric
More informationUpdate on First Psychotic Episodes in Childhood and Adolescence. Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University
Update on First Psychotic Episodes in Childhood and Adolescence Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University Childhood-Onset Psychosis 8% of psychiatrically referred youth
More informationImpact of antipsychotics on long-term course of psychotic illness. Donald Goff, MD Nathan Kline Institute NYU School of Medicine
Impact of antipsychotics on long-term course of psychotic illness Donald Goff, MD Nathan Kline Institute NYU School of Medicine Disclosures Dr. Goff receives research support from NIMH, the Stanley Foundation
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationDisease Modification in Schizophrenia: Overview of the Issues. ISCTM February 18 th 2014 Ravi Anand, MD Switzerland
Disease Modification in Schizophrenia: Overview of the Issues ISCTM February 18 th 2014 Ravi Anand, MD Switzerland Need for a New Treatment Paradigm in Schizophrenia Sixty years after approval for the
More informationPreventing psychosis and targeting people at risk: From bright idea to NICE Guidelines. Paul French
Preventing psychosis and targeting people at risk: From bright idea to NICE Guidelines Paul French Psychosis: The Early Course Adapted from Larsen et al., 2001 Early Intervention in the atrisk phase ARMS
More informationPsychotic prodrome: Are antipsychotics effective? Ethical?
Psychotic prodrome: Are antipsychotics effective? Ethical? Evidence is mixed but risk is high when abnormal cognition falls short of schizophrenia Meera Narasimhan, MD Director, psychopharmacology division
More informationNovember 2014 MRC2.CORP.X.00004
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid consultant of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationTracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health
Schizophrenia: What Do We Know? Where Do We Go From Here? Tracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health Objectives Participants will be able to: Understand the clinical
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 1 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationMeasuring the Duration of Untreated Psychosis (DUP) in First Episode Psychosis Programs
Measuring the Duration of Untreated Psychosis (DUP) in First Episode Psychosis Programs Dr. Kate Hardy, Clin.Psych.D Dr. Rachel Loewy, PhD Dr. Tara Niendam, PhD 3 Disclaimer The views, opinions, and content
More informationWhat is psychosis? The Challenge 4/11/2011. Psychotic Spectrum Symptoms in Youth
What is psychosis? Psychotic Spectrum Symptoms in Youth Nick Weiss, MD PART Program Director, Child and Adolescent Psychiatry Clinics University of California, San Francisco Often thought of as catastrophically
More informationAge / Sex: 31-year-old bi-racial male admitted to hospital through. Background:
Stephen M. Goldfinger, MD Chart Review: The Patient You Hate to Treat PATIENT INFO 31 / Male Age / Sex: 31-year-old bi-racial male admitted to hospital through Background: Psychiatric Emergency Services.
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationNIH Public Access Author Manuscript Expert Rev Neurother. Author manuscript; available in PMC 2011 June 1.
NIH Public Access Author Manuscript Published in final edited form as: Expert Rev Neurother. 2010 August ; 10(8): 1347 1359. doi:10.1586/ern.10.93. Early signs, diagnosis and therapeutics of the prodromal
More informationANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!!
More informationOptimizing Care for Patients With Schizophrenia
Optimizing Care for Patients With Schizophrenia (page 217 in syllabus) Andrew J. Cutler, MD Courtesy Assistant Professor, Department of Psychiatry University of Florida CEO and Medical Director, Florida
More informationSuboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies
Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,
More informationAt Risk Mental State but at risk of what? An opportunity for discussion. Ray McEnhill EIS Wellington
At Risk Mental State but at risk of what? An opportunity for discussion Ray McEnhill EIS Wellington ARMS UHR subgroups & transition rates Diagnoses in those with ARMS Non-converters What we re doing in
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationAuthors and Disclosures
Page 1 of 10 www.medscape.com Authors and Disclosures Interviewer Stephen M. Strakowski, MD Chairman, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine;
More informationImplementing a Community- Based Initiative for Early Treatment of Psychosis: From RAISE Connection to OnTrackNY
Implementing a Community- Based Initiative for Early Treatment of Psychosis: From RAISE Connection to OnTrackNY Lisa Dixon, M.D., M.P.H. Director, Center for Practice Innovations, NYSPI Columbia University
More informationHandout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes
Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication
More informationEarly Psychosis: A Bridge to Future
Western University Scholarship@Western Psychiatry Presentations Psychiatry 6-19-2007 Early Psychosis: A Bridge to Future Amresh Srivastava University of Western Ontario, Amresh.Srivastava@sjhc.london.on.ca
More informationRobert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014
Robert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014 Disclosures I have no personal financial relationships with commercial
More informationReview Article The promise of early intervention
Early Intervention in Psychiatry 2007; 1: 294 307 doi:10.1111/j.1751-7893.2007.00043.x Review Article The promise of early intervention Jean Addington 1,2,3 1 Department of Psychiatry, University of Toronto,
More information4. General overview Definition
4. General overview 4.1. Definition Schizophrenia is a severe psychotic mental disorder characterized by significant disturbances of mental functioning. It has also been called early dementia, intrapsychic
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationTHANK YOU FOR JOINING ISMPP U TODAY! The program will begin promptly at 11:00 am eastern
THANK YOU FOR JOINING ISMPP U TODAY! The program will begin promptly at 11:00 am eastern ISMPP WOULD LIKE TO THANK.. the following Corporate Platinum Sponsors for their ongoing support of the society ISMPP
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationClinical Staging and the At-Risk Phase of Psychotic Disorder
Clinical Staging and the At-Risk Phase of Psychotic Disorder Sabina Abidi MD FRCPC IWK Youth Psychosis Program Capital Health Nova ScoCa Early Psychosis Program Key Findings in Early Psychosis Knowledge
More informationBackground. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode
updated 2012 Duration of antipsychotic treatment in individuals with a first psychotic episode Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug
More informationResponding to the Challenge of Treatment of Individuals with Co-occurring Substance Abuse and Psychotic Disorders: A Focus on Youth and Young Adults
Responding to the Challenge of Treatment of Individuals with Co-occurring ubstance Abuse and Psychotic Disorders: A Focus on Youth and Young Adults Lisa Dixon, M.D., M.P.H. New York tate Psychiatric Institute
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationFour-Part Case Series: Treatment Challenges in Schizophrenia - Q&A Session I & II
SYLLABUS AND COURSE GUIDE Session I: Tuesday, July 11, 2017 Session II: Thursday, July 13, 2017 WC-034-071117-03 WC-035-071317-03 Four-Part Case Series: Treatment Challenges in Schizophrenia - Q&A Session
More informationRUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1
RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1 Efficacy of Long Acting Injectable Antipsychotics in Early Onset Schizophrenia Linda Pietras RN-BC Mercyhurst University
More informationSchizophrenia: Early Intervention
Focus on CME at The University of Western Ontario Schizophrenia: Early Intervention Rahul Manchanda, MD, MRCPsych, FRCP(C); and Ross M.G. Norman, PhD, CPsych Presented at A Psychiatric Update 2003, Regional
More informationEVIDENCE AND PERSPECTIVES IN EARLY RECOGNITION AND INTERVENTION FOR PSYCHOSIS and BEYOND. Patrick McGorry
EVIDENCE AND PERSPECTIVES IN EARLY RECOGNITION AND INTERVENTION FOR PSYCHOSIS and BEYOND Patrick McGorry TOTAL IEPA MEMBERS PER YEAR 3000 2900 2500 2000 1500 1000 1127 1328 1540 1828 1856 2090 2133 2489
More informationPsychopharmacological treatment of first episode psychosis
Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center
More informationInitial Prodrome Description in Recent Onset Schizophrenia
Amr El-Shribiny et al. Initial Prodrome Description in Recent Onset Schizophrenia Amr M M El-Shribiny, Salwa M. Rabie, Hanaa S. Soliman, Refaat Mahfouz Department of Neurology and Psychiatry, El-Minia
More informationEarly detection and intervention of psychosis
Early detection and intervention of psychosis New Data Benno G. Schimmelmann University Hospital of Child and Adolescent Psychiatry Bern, Bern, Switzerland Early detection of psychosis Early Detection
More informationEarly Psychosis Services: Philadelphia PEACE Program
Early Psychosis Services: Philadelphia PEACE Program Irene Hurford, M.D. Clinical Director, PEACE Program, Horizon House Assistant Professor, Department of Psychiatry, University of Pennsylvania 1 John
More informationIs there a case for earlier use of antipsychotic LAIs in schizophrenia? John Donoghue Liverpool
Copyright John Donoghue 2017 Is there a case for earlier use of antipsychotic LAIs in schizophrenia? John Donoghue Liverpool If not us, then who? If not now, when? Attributed at different times to: Hillel
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationTopography and significance of the dopaminergic dysfunction in schizophrenia
Topography and significance of the dopaminergic dysfunction in schizophrenia Anissa Abi-Dargham MD Professor of Psychiatry and Vice Chair for Research Department of Psychiatry Stony Brook University Professor
More informationNumber needed to treat (NNT) is a measure of
For mass reproduction, content licensing and permissions contact Dowden Health Media. p sychiatry Can you interpret confidence intervals? It s not that difficult NNT medicine s secret stat offers infinite
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 2 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationHow should we intervene in psychosis risk syndromes?
How should we intervene in psychosis risk syndromes? The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Wang, Jijun, Kaida
More informationClinical Use of Ketamine in Psychiatry
Clinical Use of Ketamine in Psychiatry C. Sophia Albott, MD, MA Assistant Professor Department of Psychiatry and Behavioral Sciences University of Minnesota Medical School November 17, 2018 Disclosure
More informationIndividualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool
Copyright John Donoghue 2015 Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 QUESTIONS Why do outcomes in schizophrenia remain
More informationDr. Jean Addington Annual Report
Alberta Centennial Mental Health Research Chairs Program Dr. Jean Addington Annual Report website version Dr. Jean Addington Alberta Centennial Mental Health Research Chair Inaugural Chair in Child and/or
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationEffects of acute ketamine infusion on visual working memory encoding: a study using ERPs
Effects of acute ketamine infusion on visual working memory encoding: a study using ERPs Corinna Haenschel Psychology, City University London, UK Partly Funded by: the Welsh Institute of Cognitive Neuroscience
More informationDurham Research Online
Durham Research Online Deposited in DRO: 14 May 2013 Version of attached file: Peer-review status of attached file: Peer-reviewed Citation for published item: Welsh, P. (2009) Psychology and the At risk
More information10 INDEX Acknowledgements, i
INDEX 10 INDEX Acknowledgements, i Acute Care, Admissions to, 3.83 Discharge Planning, 3.86 Involuntary Admission Criteria, 3.84 List of Designated Provincial and Regional Mental Health Facilities, 3.83
More informationInsight in Mental Illness:
Insight in Mental Illness: Impact on Adverse Effects, Functional Outcome and Treatment Adherence Joseph F. Goldberg, M.D. Clinical Professor of Psychiatry Icahn School of Medicine at Mount Sinai New York,
More informationLonasen (Blonanserin) Lullan (Perospirone) Saphris/Sycrest (Asenapine, ORG 5222, SCH ) Saphris/Sycrest (Continued)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psychosis and schizophrenia in children and young people: recognition and management 1.1 Short title Psychosis and schizophrenia
More informationSchizophrenia and Related Psychotic Disorders
and Related Psychotic Disorders Anand K. Pandurangi, MD Professor & Chair, Div. of Inpatient Psychiatry Director, Program VCU Medical Center 1 Kraeplin 1896 Dementia Praecox. Single, Homogenous Disorder
More informationSchizoaffective Disorder
Schizoaffective Disorder combination of schizophrenia symptoms (hallucinations or delusions) and mood disorder symptoms (such as mania or depression.) Controversial Requires presence of delusions for 2
More informationOpen Translational Science in Schizophrenia. Harvard Catalyst Workshop March 24, 2015
Open Translational Science in Schizophrenia Harvard Catalyst Workshop March 24, 2015 1 Fostering Use of the Janssen Clinical Trial Data The goal of this project is to foster collaborations around Janssen
More informationThe British Approach to Understanding and Treating Psychosis
The British Approach to Understanding and Treating Psychosis Robin M Murray Professor of Psychiatric Research Department of Psychosis Studies Institute of Psychiatry robin.murray@kcl.ac.uk Which boy will
More informationA Conversation about Psychosis: Recognizing and Responding to Risk. Janine Rodenhiser-Hill, Ph.D.
A Conversation about Psychosis: Recognizing and Responding to Risk Janine Rodenhiser-Hill, Ph.D. www.cedarclinic.org Commonwealth Research Center/DMH Massachusetts Mental Health Center Beth Israel Deaconess
More informationSocial anxiety disorder in early phase psychosis: the role of shame sensitivity and diagnosis concealment
Social anxiety disorder in early phase psychosis: the role of shame sensitivity and diagnosis concealment Max Birchwood www.youthspace.me Affect and psychosis: much more than a co-morbidity Affective
More informationProgram Outline. DSM-5 Schizophrenia Spectrum and Psychotic Disorders: Knowing it Better and Improving Clinical Practice.
DSM-5 Spectrum and Disorders: Knowing it Better and Improving Clinical Practice Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Program Outline Changes
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena Otsuka Pharmaceuticals Co. & Lundbeck Canada Inc.) Indication: Schizophrenia Recommendation: The Canadian Drug Expert Committee
More informationThe scope of the problem. Literature review
Past Year: Novartis Ever: Alkermes, Amylin, Behringer- Ingelheim, Biovail, Bristol-Myers Squibb, Eli Lilly, Embryon, GlaxoSmithKline, Merck, Organon, Park-Davis, Pfizer, Sanolfi-Aventis, Smith-Kline Beacham,
More informationEarly Intervention in Psychosis... Dec 7 th Wakefield
Early Intervention in Psychosis... Dec 7 th Wakefield David.Shiers@doctors.org.uk Declaration of Interest: 1. Member of two Guideline Development Groups (GDG) for NICE: a) NICE guidance for children and
More informationLearn how you can support
Learn how you can support Sponsored by Otsuka Pharmaceutical Development and Commercialization, Otsuka America Pharmaceutical, Inc., Lundbeck, L.L.C. and Avanir Pharmaceuticals, Inc. 2016 Otsuka Pharmaceutical
More informationSchizophrenia: New Concepts for Therapeutic Discovery
Schizophrenia: New Concepts for Therapeutic Discovery William T. Carpenter, M.D. Professor of Psychiatry and Pharmacology University of Maryland School of Medicine Department of Psychiatry Maryland Psychiatric
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationSchizophrenia: inorganic no more
Schizophrenia: inorganic no more Michael A P Bloomfield PhD 1,2, S Caroline Buck MBChB 2, *Oliver D Howes DM 1,3 1 Psychiatric Imaging Group, MRC Clinical Sciences Centre, Institute of Clinical Sciences,
More informationAre they still doing that?
Are they still doing that? Why we still give ECT and when to refer Nicol Ferrier BSc (Hons), MD, FRCP(Ed), FRCPsych Emeritus Professor of Psychiatry Newcastle University Rates of prescribing ECT in the
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abuse substance. See Substance abuse Acquired disorders presenting as psychosis in children and young adults, 581 608. See also specific
More informationClinical Update on the Management of Schizophrenia
Clinical Update on the Management of Schizophrenia L. Fredrik Jarskog, M.D. Professor of Psychiatry Research Director, North Carolina Psychiatric Research Center UNC-Chapel Hill Disclosures Past 3 years:
More informationIdentifying Schizophrenia: Paradigm Shift The UHR Research
Western University Scholarship@Western Psychiatry Presentations Psychiatry 1-12-2009 Identifying Schizophrenia: Paradigm Shift The UHR Research Amresh Srivastava University of Western Ontario, Amresh.Srivastava@sjhc.london.on.ca
More informationStigma, well-being, attitudes to service use and transition to schizophrenia: Longitudinal findings among young people at risk of psychosis
Stigma, well-being, attitudes to service use and transition to schizophrenia: Longitudinal findings among young people at risk of psychosis Nicolas Rüsch, Mario Müller, Karsten Heekeren, Ana Theodoridou,
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationAT RISK MENTAL STATES FOR PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE: RECOGNITION AND MANAGEMENT
APPENDIX 13A: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: AT RISK MENTAL STATES FOR PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE: RECOGNITION AND MANAGEMENT Abbreviations... 2 Included
More informationBarcelona October 26-27, Abstracts Symposiums
Barcelona October 26-27, 2017 Abstracts Symposiums INDEX Symposiums Title Page 1. Gender differences in emerging psychosis 2 2. Psychosis and gender: Do reproductive phases matter?. 6 3. Sex, hormones
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationc01 WU083-French January 22, :40 Char Count= 0 PART I BACKGROUND 1
PART I BACKGROUND 1 THE IMPORTANCE OF EARLY RECOGNITION RATIONALE The length of time between the onset of psychotic symptoms and the subsequent detection, diagnosis and commencement of treatment has been
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationEarly Stages of Psychosis. Learning Objectives
Early Stages of Psychosis Stephan Heckers, MD MSc Department of Psychiatry and Behavioral Sciences Vanderbilt University Learning Objectives Summarize the five domains of psychosis Describe how psychotic
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCharles H. Kellner, MD
ECT: Learning From Recent Trials Charles H. Kellner, MD Professor, Department of Psychiatry Icahn School of Medicine at Mount Sinai ISCTM Philadelphia, PA 27 September, 2016 Charles H. Kellner, MD Disclosures
More informationWorking with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers
Working with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers Tuesday, February 23, 2016 2pm Eastern Delbert Robinson, M.D. Professor of Psychiatry and Molecular Medicine
More informationPharmacotherapy of ADHD with Non- Stimulants
Pharmacotherapy of ADHD with Non- Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationDRAFT SLIDES. Michael Huss Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany
DRAFT SLIDES Separating efficacy and sedative effects of guanfacine extended release in children and adolescents with ADHD from four randomized, controlled, phase 3 clinical trials Michael Huss Child and
More information